CCI
VNDA icon

Columbus Circle Investors’s Vanda Pharmaceuticals VNDA Stock Holding History

Columbus Circle Investors’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-57,310
Closed -$1.03M – 275
2017
Q3 		$1.03M Sell
57,310
-12,794
-18% -$214K 0.02% 266
2017
Q2 		$1.14M Sell
70,104
-20,945
-23% -$302K 0.02% 222
2017
Q1 		$1.27M Buy
91,049
+5,742
+7% +$81.8K 0.02% 240
2016
Q4 		$1.36M Buy
85,307
+1,196
+1% +$19.2K 0.02% 227
2016
Q3 		$1.4M Buy
84,111
+17,633
+27% +$237K 0.02% 243
2016
Q2 		$744K Sell
66,478
-38,096
-36% -$369K 0.01% 239
2016
Q1 		$874K Buy
+104,574
New +$858K 0.01% 243
2015
Q4 		– Sell
-47,258
Closed -$533K – 311
2015
Q3 		$533K Buy
+47,258
New +$578K ﹤0.01% 264
2014
Q1 		– Sell
-196,358
Closed -$2.44M – 327
2013
Q4 		$2.44M Buy
196,358
+155,951
+386% +$1.57M 0.02% 260
2013
Q3 		$442K Buy
40,407
+7,907
+24% +$84.5K ﹤0.01% 288
2013
Q2 		$263K Buy
+32,500
New +$219K ﹤0.01% 274

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Columbus Circle Investors's VNDA Position: Q4 2017 in Review

Columbus Circle Investors sold out of Vanda Pharmaceuticals (VNDA) in Q4 2017, closing a stake of 57,310 shares — an estimated $1.03M sold.

Columbus Circle Investors first reported a position in VNDA in Q2 2013 and held it in 11 quarters. The position peaked at $2.44M in Q4 2013. 125 funds tracked by Wall St. Rank hold VNDA as of Q4 2017.

  • Columbus Circle Investors reported no remaining Vanda Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Columbus Circle Investors sold 57,310 Vanda Pharmaceuticals shares in Q4 2017, an estimated $1.03M.
  • Columbus Circle Investors first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 11 quarters.
  • Columbus Circle Investors's Vanda Pharmaceuticals position peaked at $2.44M in Q4 2013.
  • 125 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2017.

Based on Columbus Circle Investors's 13F filing for Q4 2017, filed 2 Feb 2018.